What are China's pharmaceutical stocks?

China's pharmaceutical stocks, covering the entire industry chain of pharmaceutical research and development, production and sales, with strong industrial strength and core competitive advantages. Benefiting from the national policy support and market demand growth, the company's business scale continues to expand, performance continues to grow steadily. The following Xiao Biao brought China's pharmaceutical stocks are which, we take a look at it, I hope to bring reference.

China's pharmaceutical stocks are which

1, Hengrui Medicine

Jiangsu Hengrui Medicine Co., Ltd. is approved by the People's Government of Jiangsu Province, by Lianyungang Hengrui Group Co., Ltd. and other five sponsors in April 1997 **** with the establishment of a joint stock limited company, is the largest anti-tumor It is the largest research and production base of anti-tumor drugs in China.

2, East China Pharmaceutical

Hangzhou East China Pharmaceutical Group Company formerly known as Zhejiang Pharmaceutical Factory, founded in 1952, later renamed Hangzhou Second Pharmaceutical Factory, Hangzhou East China Pharmaceutical Factory.

On December 16, 1992, Hangzhou Huadong Pharmaceutical Group Company was established on the basis of Hangzhou Huadong Pharmaceutical Factory, which has developed into a joint-stock enterprise--Huadong Pharmaceuticals Co., Ltd. and four Sino-foreign equity joint ventures (Hangzhou Zhongmei Huadong Pharmaceutical Co.) and more than 10 other holding pharmaceutical enterprises.

3, Huahai Pharmaceutical

Zhejiang Huahai Pharmaceutical Co., Ltd. was founded in 1989, its predecessor is Linhai City flood bridge synthetic chemical plant, in January 2001, the whole change was set up for the establishment of Zhejiang Huahai Pharmaceutical Company Limited.

3, the company's shares were successfully listed on the Shanghai Stock Exchange. Stock abbreviation: Huahai Pharmaceuticals, stock code: 600521.

4, Puli Pharmaceutical

Hainan Puli Pharmaceuticals Co., Ltd. was founded in 1992, is specialized in the research and development of chemical pharmaceutical preparations, production and sales of high-tech enterprises, has been through the China's pharmaceutical enterprises internationalization of the preparations of the pilot enterprise certification. The company has two wholly-owned subsidiaries, Zhejiang Puli Pharmaceutical Co., Ltd. and Hangzhou Saili Pharmaceutical Research Institute.

5, Jingxin Pharmaceutical

Zhejiang Jingxin Pharmaceutical Co., Ltd. was founded in 1974, has developed into a national key high-tech enterprises, China's top 100 pharmaceutical companies, in July 2004, successfully listed on the Shenzhen Stock Exchange.

6, Xinlitai

Shenzhen Xinlitai Pharmaceutical Co., Ltd. is approved by the Ministry of Commerce of the People's Republic of China *** and the Ministry of Commerce "Ministry of Commerce on the consent of Shenzhen Xinlitai Pharmaceutical Co., Ltd. restructuring into a sino-foreign equity joint venture approved by the Ministry of Commerce" (business capital approval [2007] No. 1016), and to obtain the Ministry of Commerce issued by the "People's Republic of China *** and the State of Taiwan, Hong Kong and Macao investment enterprises approved certificate", in June 2007, in the Ministry of Commerce of the People's Republic of China and the State of Taiwan, Hong Kong and Macao investment enterprises approved certificate. Certificate", on June 29, 2007 by the Shenzhen Xinlitai Pharmaceutical Co., Ltd. (hereinafter referred to as "Shenzhen Xinlitai") was established in accordance with the overall change of foreign-invested joint stock limited company, the registered capital of 85 million yuan, and at the same time to receive the business license of the enterprise legal person, registration No.: 440301501124347.

China Pharmaceuticals What is the stock code?

China Pharmaceutical's stock code is 600056, if you want to know more information, you can download a stock software to check, I hope the answer is helpful to you.

Can China Pharma stocks be held for the long term

Yes. Although China's pharmaceutical stock bubble has been heavy relative to foreign countries, it is still a good variety of anti-inflation and anti-economic cycle with continued policy support.

China Pharmaceutical Group Limited is the only central pharmaceutical enterprise directly managed by the State Council's State-owned Assets Supervision and Administration Commission (SASAC) with the pharmaceutical and health industry as its main business, founded in 1998, is the leading comprehensive life and health industry group in China and Asia in terms of comprehensive strength and scale.

The enterprise owns a large health industry chain integrating scientific and technological research and development, industrial manufacturing, logistics and distribution, retail chain, medical and healthcare, international operation and financial investment.

On August 2, 2021, the 2021 Fortune Global 500 list was released, and China Pharmaceutical Group Corporation was ranked 109th.

China National Pharmaceutical Group is making every effort to promote the comprehensive construction of the Group's five platforms - modern logistics distribution integrated operation platform, industry-academia-research integrated science and technology innovation platform, international operation integrated platform, medical and healthcare industry platform, and highly efficient control and integration and synergy integrated platform - and to form five full-coverage networks --National pharmaceutical logistics distribution network, national pharmaceutical retail chain network, national narcotic drugs distribution network, national biological products marketing and cold chain distribution network, and national medical equipment consumables distribution network, to promote the Group's eleven major businesses-medicine Modern logistics distribution, pharmaceutical retailing, biological products, chemical pharmaceuticals, modern traditional Chinese medicine, diagnostic reagents and chemical reagents, scientific instruments and medical devices, pharmaceutical scientific research and engineering design, pharmaceutical international operations and overseas industries, pharmaceutical exhibitions and media, and the comprehensive development of the medical and healthcare industry, constituting a pharmaceutical and healthcare industry as the core competitiveness of an innovative enterprise.

Pharmaceutical Group has a pharmaceutical distribution network covering 31 provinces, autonomous regions and municipalities directly under the Central Government and 30 distribution centers in line with international standards, is the largest biopharmaceutical research and development, production enterprises in China, China, to undertake more than 80% of the national immunization plan for the production of vaccines. The Group has established production bases and herb bases for biopharmaceuticals, narcotic psychotropic drugs, anti-infectives, anti-tumor drugs, cardio-cerebral and cerebrovascular drugs, respiratory drugs, etc., and possesses the strongest applied pharmaceutical research institutes and engineering design institutes in China.

Why can't China's pharmaceutical stocks be bought

Because the Internet channel is not available. According to the query of China's pharmaceutical stock information, China's pharmaceutical stock can not be bought because the Internet channel can not be purchased. China Pharmaceuticals said on December 26, 2022, Pfizer's new crown oral drug Paxlovid is a prescription drug that needs to be purchased according to the hospital's diagnosis, and can not be purchased on the Internet channel.

China Pharmaceutical Group Limited is the only centralized pharmaceutical enterprise directly managed by the State-owned Assets Supervision and Administration Commission of the State Council that focuses on the pharmaceutical and healthcare industry. Founded in 1998, the company is a comprehensive life and healthcare industry group with leading comprehensive strength and scale in China and Asia.

On August 2, 2021, the 2021 Fortune Global 500 list was released, and China Pharmaceutical Group Corporation was ranked 109th.

China National Pharmaceutical Group is making every effort to promote the comprehensive construction of the Group's five platforms - modern logistics distribution integrated operation platform, industry-academia-research integrated science and technology innovation platform, international operation integrated platform, medical and healthcare industry platform, and highly efficient control and integration and synergy integrated platform - and to form five full-coverage networks --National pharmaceutical logistics distribution network, national pharmaceutical retail chain network, national narcotic drugs distribution network, national biological products marketing and cold chain distribution network, and national medical equipment consumables distribution network, to promote the Group's eleven major businesses-medicine Modern logistics distribution, pharmaceutical retailing, biological products, chemical pharmaceuticals, modern traditional Chinese medicine, diagnostic reagents and chemical reagents, scientific instruments and medical devices, pharmaceutical scientific research and engineering design, pharmaceutical international operations and overseas industries, pharmaceutical exhibition and media, and the comprehensive development of the medical and health industry, constituting an innovative enterprise with the pharmaceutical and health industry as its core competitiveness.

Pharmaceutical stocks can be bought now

Can be bought. In the long run, the trend of making money in the pharmaceutical industry still exists.

According to relevant data reports: the current per capita medical expenditure in China is only 420 U.S. dollars, while the United States up to 9403 U.S. dollars, Japan is 3703 U.S. dollars. China's demographic structure, development trend and Japan are very similar, compared to the per capita medical expenditure, there is a nine-fold increase in space. In the long term, with the arrival of the trend of population aging, the pharmaceutical industry will be a gold mine that investors can not ignore. The short and medium term coupled with the outbreak of the new crown epidemic in 2020, more accelerated the outbreak of profits, performance, and capital attention of the pharmaceutical industry. As of the end of December 2021, the total market value of A shares is about 80 trillion, and the pharmaceutical industry accounts for about 9%. Ten years ago, this figure was only 3%. With the upgrading of medical consumption, population aging is coming, and the new crown is delayed? The pharmaceutical industry has a huge future. There are the following two reasons:

One, the aging of the population, the demand for health care has exploded growth. We can certainly all feel: the trend of population aging in China is gradually significant. This trend we can use some data to illustrate: as of the end of 2017, China's population over 65 years old is 158 million, accounting for 11.39% of the total population, and the growth rate of the population over 65 years old has always remained at about 10%. And the probability of human disease will gradually rise with age, according to the China Health Statistics Yearbook forecast: the number of chronic diseases in China's elderly population is increasing.

Two, the pharmaceutical industry's defensive attributes, loved by institutions. Pharmaceutical industry is a typical weak cyclical industry, demand rigidity, elasticity is small, by the macroeconomic impact is small. Thus, the pharmaceutical industry has strong defensive characteristics. Even if the whole country's macroeconomic downturn, the pharmaceutical industry index is likely to rise well. Take the Japanese stock market as an example. From 1992 to 2012, the Japanese economy into the "lost two decades". Nikkei fell 25.6%, while the pharmaceutical industry index rose 92%, there are 14 years of pharmaceutical industry index have outperformed the Nikkei. On the contrary, the A-share market has a tradition of "drinking and taking medicine". When the market is bad, institutional funds will embrace white wine stocks and pharmaceutical stocks. No other, white wine and medicine have performance support only. White wine and medicine has also been the institution's heart good. Now the haze, gutter oil and other issues, the future of the country's body will have how the disease, it is not easy to say, but can be sure of one thing, the future demand for drugs will be great. Industry demand is strong, the market recognition is strong. This is the core reason for the myth that the pharmaceutical industry has been making money for a long time. Overall, the pharmaceutical industry is a track worthy of our long-term attention.